Show items per page
Elements: 4
Page 1 on 1
 TitleAuthors / EditorsDate
add to browser selection
Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial Cahn, Pedro; Kaplan, Richard; Sax, Paul E; Squires, Kathleen; ... Calmy, Alexandra 2017
add to browser selection
Preferred antiretroviral drugs for the next decade of scale up Andrieux-Meyer, Isabelle; Calmy, Alexandra; Cahn, Pedro; Clayden, Polly; ... Ford, Nathan 2012
add to browser selection
The Monark trial: where now for boosted protease inhibitor monotherapy? Hill, Andrew; Hirschel, Bernard; Katlama, Christine 2008
add to browser selection
Characterization of genotypic determinants in HR-1 and HR-2 gp41 domains in individuals with persistent HIV viraemia under T-20 Marcelin, A. G.; Reynes, Jacques; Yerly Ferrillo, Sabine; Ktorza, Nadine; ... Calvez, Vincent 2004